Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Non-Current Assets (2017 - 2025)

Arcus Biosciences (RCUS) has 9 years of Non-Current Assets data on record, last reported at $125.0 million in Q1 2025.

  • For Q1 2025, Non-Current Assets changed N/A year-over-year to $125.0 million; the TTM value through Mar 2025 reached $876.0 million, changed N/A, while the annual FY2023 figure was $264.0 million, 13.3% up from the prior year.
  • Non-Current Assets reached $125.0 million in Q1 2025 per RCUS's latest filing, down from $178.0 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $330.0 million in Q4 2021 and bottomed at $93.2 million in Q1 2021.
  • Average Non-Current Assets over 5 years is $233.8 million, with a median of $244.1 million recorded in 2022.
  • Peak YoY movement for Non-Current Assets: surged 2018.78% in 2021, then fell 29.39% in 2022.
  • A 5-year view of Non-Current Assets shows it stood at $330.0 million in 2021, then dropped by 29.39% to $233.0 million in 2022, then grew by 13.3% to $264.0 million in 2023, then crashed by 32.58% to $178.0 million in 2024, then fell by 29.78% to $125.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $125.0 million in Q1 2025, $178.0 million in Q2 2024, and $264.0 million in Q4 2023.